Vitro method and apparatus for analysing the behaviour of substances in simulated physiological environment

US10746644B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10746644-B2
Application numberUS-201916577431-A
CountryUS
Kind codeB2
Filing dateSep 20, 2019
Priority dateAug 20, 2014
Publication dateAug 18, 2020
Grant dateAug 18, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention refers to an in vitro method and apparatus for analysing the behaviour of substances in simulated physiological environment. The method comprises the steps of providing a first fluid, a gel matrix and a second fluid, separating the first fluid and the gel matrix by at least one first semi-permeable membrane and separating the gel matrix and the second fluid by at least one second semi-permeable membrane. The method further comprises the steps of injecting a substance into the first fluid, letting the substance migrate from the first fluid through the at least one first semi-permeable membrane, through the gel matrix, through the at least one second semi-permeable membrane and into the second fluid, and determining clearance of the substance from the first fluid.

First claim

Opening claim text (preview).

The invention claimed is: 1. An apparatus for analyzing the behaviour of molecules in simulated physiological environment, the apparatus comprising a first compartment for receiving a first fluid, a second compartment for receiving a gel matrix, and a third compartment for receiving a second fluid; the apparatus further comprising at least one first semi-permeable membrane, and at least one second semi-permeable membrane, the at least one second semi-permeable membrane being arranged at a distance from the at least one first semi-permeable membrane, wherein the at least one first semi-permeable membrane is arranged between the first compartment and the second compartment, and wherein the at least one second semi-permeable membrane is arranged between the second compartment and the third compartment, wherein the first compartment, the second compartment and the third compartment are arranged in a row, and wherein the at least one first semi-permeable membrane and the at least one second semi-permeable membrane are arranged substantially vertically between the respective compartments, the apparatus further comprising holders for holding the at least one first semi-permeable membrane and the at least one second semi-permeable membrane between the respective compartments, and wherein the holders do not extend into any of the first, second or third compartment. 2. The apparatus according to claim 1 , wherein a Molecular Weight Cut Off (MWCO) of the at least one first semi-permeable membrane substantially corresponds to the Retinal Exclusion Limit (REL). 3. The apparatus according to claim 1 , wherein the at least one first semi-permeable membrane has a Molecular Weight Cut Off (MWCO) being smaller than or equal to the Molecular Weight Cut Off (MWCO) of the at least one second semi-permeable membrane. 4. The apparatus according to claim 1 , wherein the at least one first semi-permeable membrane has a concave shape. 5. The apparatus according to claim 1 , wherein the at least one second semi-permeable membrane has a concave shape. 6. The apparatus according to claim 1 , comprising or being made of glass. 7. The apparatus according to claim 1 , further comprising a first support for supporting the at least one first semi-permeable membrane. 8. The apparatus according to claim 7 , wherein the first support has a concave shape. 9. The apparatus according to claim 1 , further comprising a second support for supporting the at least one second semi-permeable membrane. 10. The apparatus according to claim 9 , wherein the second support has a concave shape. 11. The apparatus according to claim 1 , wherein the first compartment comprises the first fluid, which first fluid is vitreous humor. 12. The apparatus according to claim 1 , wherein the third compartment comprises the second fluid, which second fluid is a buffer solution. 13. The apparatus according to claim 12 , wherein the buffer solution is a physiologically relevant buffer solution. 14. A method of using the apparatus according to claim 1 for in vitro testing a substance for determining stability or bioavailability of the substance, comprising: providing the apparatus of claim 1 ; providing a first fluid, a gel matrix and a second fluid; separating the first fluid and the gel matrix by at least one first semi-permeable membrane; separating the gel matrix and the second fluid by at least one second semi-permeable membrane; injecting a substance into the first fluid; letting the substance migrate from the first fluid through the at least one first semi-permeable membrane, through the gel matrix, through the at least one second semi-permeable membrane and into the second fluid; removing a sample from the first fluid and from the second fluid; and measuring the substance concentration in the first fluid, in the second fluid or in both, the first and the second fluid, wherein the measurements are performed over several hours up to one or two weeks or longer. 15. The method of claim 14 , wherein the substance is a drug formulation. 16. The method of claim 14 , wherein the substance comprises molecules having a size in a range between about 1 kDa and about 250 kDa. 17. The method of claim 14 , wherein the substance comprises molecules having a size in a range between 4 kDa and 150 kDa.

Assignees

Inventors

Classifications

  • Biological material, e.g. blood, urine (G01N33/02, G01N33/26, G01N33/44, G01N33/46 take precedence); Haemocytometers (counting blood corpuscules distributed over a surface by scanning the surface G06M11/02) · CPC title

  • Medicinal preparations {; Physical properties thereof, e.g. dissolubility} · CPC title

  • G01N13/00Primary

    Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects (scanning-probe techniques or apparatus G01Q) · CPC title

  • through a gel, e.g. Ouchterlony technique · CPC title

  • Diffusion; diffusivity between liquids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10746644B2 cover?
The invention refers to an in vitro method and apparatus for analysing the behaviour of substances in simulated physiological environment. The method comprises the steps of providing a first fluid, a gel matrix and a second fluid, separating the first fluid and the gel matrix by at least one first semi-permeable membrane and separating the gel matrix and the second fluid by at least one second …
Who is the assignee on this patent?
Hoffmann La Roche
What technology area does this patent fall under?
Primary CPC classification G01N13/00. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).